Publicacións en colaboración con investigadores/as de Hospital Universitario de Salamanca (14)

2024

  1. Thrombotic risk and features of patients with inferior vena cava agenesis: a multicentre, retrospective, observational study

    The Lancet Haematology, Vol. 11, Núm. 8, pp. e606-e616

2023

  1. Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study

    Neurology and Therapy, Vol. 12, Núm. 6, pp. 2177-2193

2022

  1. Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 11, pp. 1196-1205

  2. The role of PSMA radioligands in the diagnosis and treatment of prostate carcinoma

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 41, Núm. 2, pp. 126-135

2021

  1. The 18F phantom clinical trials qualification for 18F-FDG-PET scanning adopted by GELTAMO (Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea)

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 40, Núm. 3, pp. 149-154

2020

  1. A novel Col4A1 mutation: recognizing an uncommon cause of stroke

    European Journal of Neurology

  2. FDG PET/CT in colorectal cancer

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 39, Núm. 1, pp. 57-66

  3. Phase II Trial of Palbociclib in Recurrent Retinoblastoma-Positive Anaplastic Oligodendroglioma: A Study from the Spanish Group for Research in Neuro-Oncology (GEINO)

    Targeted Oncology, Vol. 15, Núm. 5, pp. 613-622

2018

  1. Procedimientos recomendados para el control de calidad de IMRTen tomoterapia

    Revista de Física Médica, Vol. 19, Núm. 2, pp. 73-102

2016

  1. Corrigendum to "Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance". [Rep. Pract. Oncol. Radiother. 20 (2015) 259-272]

    Reports of Practical Oncology and Radiotherapy

  2. Late Radiation and Cardiovascular Adverse Effects After Androgen Deprivation and High-Dose Radiation Therapy in Prostate Cancer: Results From the DART 01/05 Randomized Phase 3 Trial

    International Journal of Radiation Oncology Biology Physics, Vol. 96, Núm. 2, pp. 341-348

2015

  1. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): A randomised, controlled, phase 3 trial

    The Lancet Oncology, Vol. 16, Núm. 3, pp. 320-327

  2. Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance

    Reports of Practical Oncology and Radiotherapy, Vol. 20, Núm. 4, pp. 259-272

2011

  1. Non-mucinous bronchioloalveolar type pulmonary adenocarcinoma

    Revista de Patologia Respiratoria, Vol. 14, Núm. 4, pp. 150-152